Circulating tumour cells in locally advanced breast cancer

被引：10

作者：

Angel Garcia-Saenz, Jose ^{[1
]}

Martin, Miguel ^{[1
]}

Luisa Maestro, Maria ^{[2
]}

Vidaurreta, Marta ^{[2
]}

Veganzones, Silvia ^{[1
]}

Rafael, Sara ^{[2
]}

Casado, Antonio ^{[1
]}

Bobokova, Jana ^{[1
]}

Sastre, Javier ^{[1
]}

De la Orden, Virginia ^{[2
]}

Arroyo, Manuel ^{[2
]}

Diaz-Rubio, Eduardo ^{[1
]}

机构：

[1] Hosp Univ San Carlos, Med Oncol Serv, ES-28040 Madrid, Spain

[2] Hosp Univ San Carlos, Serv Anal Clin, Madrid, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2009年 / 11卷 / 08期

关键词：

Locally advanced breast cancer (LABC); Circulating tumour cells (CTCs); PERIPHERAL-BLOOD; SURVIVAL;

D O I：

10.1007/s12094-009-0400-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A prospective study was conducted to determine the value of changes in circulating tumour cell (CTC) levels prior to and after the first cycle of neoadjuvant treatment in early prediction of pathologic response in locally advanced breast cancer (LABC). Two blood samples were obtained from 72 eligible LABC patients to isolate and enumerate CTCs before neoadjuvant chemotherapy started on day 1, and on day 21, immediately before second cycle administration. Sixty patients (83.3%) had < 1 CTC in the first sample and response rates in this cohort were pathologic complete response (PCR) in 2 patients (5%), partial response (PR) in 35 (87.5%), stable disease (SD) in 2 (5%) and progressive disease (PD) in 1 (2.5%). Twelve patients (16.7%) had > 2 CTCs in the first sample; these patients were more likely to have triple negative tumours. All 12 had fewer CTCs in the second sample. Response rates in this second cohort of 12 patients were PCR in 4 (34%), PR in 6 (50%), SD in 1 (8%) and PD in 1 (8%). PCR rate was markedly better in this second cohort (p < 0.0042; OR 14.5, 95% CI 2.3-92). This study suggests that the presence of CTCs prior to neoadjuvant therapy might be a predictor of response to this therapy.

引用

页码：544 / 547

页数：4

共 16 条

[1] Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases [J].